VALacyclovir In Delaying Antiretroviral Treatment Entry.

Trial Profile

VALacyclovir In Delaying Antiretroviral Treatment Entry.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections; HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms VALIDATE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Primary endpoint (Annual rate of change in CD4 count, calculated as the slope of participants CD4 count change / time.) has not been met.
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top